candesartan has been researched along with Cognitive Decline in 8 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
Excerpt | Relevance | Reference |
---|---|---|
"To assess whether long-term treatment with candesartan/hydrochlorothiazide, rosuvastatin, or their combination can slow cognitive decline in older people at intermediate cardiovascular risk." | 3.91 | Effects of blood pressure and lipid lowering on cognition: Results from the HOPE-3 study. ( Avezum, A; Bosch, J; Dagenais, G; Dans, A; Diaz, R; Hart, R; Held, C; Keltai, M; Khunti, K; Lee, SF; Leiter, LA; Lewis, BS; Lonn, EM; O'Donnell, M; Pogue, JM; Reid, C; Sharma, M; Sliwa, K; Swaminathan, B; Toff, WD; Yusuf, S, 2019) |
" Therefore, in the current study we examined the effects of Candesartan and Compound 21 (C21) (RAS modulators) on aspects of cognition known to diminish with advanced age and accelerate with hypertension and vascular disease." | 3.88 | Role of angiotensin system modulation on progression of cognitive impairment and brain MRI changes in aged hypertensive animals - A randomized double- blind pre-clinical study. ( Ahmed, HA; Arbab, AS; Bunting, KM; Ergul, A; Fagan, SC; Ishrat, T; Patel, A; Pillai, B; Vazdarjanova, A; Waller, JL, 2018) |
"Candesartan was associated with improved whole brain CVR compared to placebo in the CEDAR study (adjusted within-group mean difference for candesartan = 0." | 3.01 | Effects of candesartan on cerebral microvascular function in mild cognitive impairment: Results of two clinical trials. ( Hajjar, I; Henley, B; Kulshreshtha, A; Okafor, M; Trammell, A, 2023) |
"Candesartan was also superior to lisinopril on the secondary outcome of Hopkins Verbal Learning Test-Revised delayed recall (ES = 0." | 2.94 | Effects of Candesartan vs Lisinopril on Neurocognitive Function in Older Adults With Executive Mild Cognitive Impairment: A Randomized Clinical Trial. ( Dee, E; Goldstein, F; Hajjar, I; Levey, A; McDaniel, D; Obideen, M; Okafor, M; Quyyumi, AA; Shokouhi, M, 2020) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 5 (62.50) | 24.3611 |
2020's | 3 (37.50) | 2.80 |
Authors | Studies |
---|---|
Henley, B | 1 |
Okafor, M | 2 |
Kulshreshtha, A | 1 |
Trammell, A | 1 |
Hajjar, I | 3 |
Kulisevsky, J | 1 |
Martínez-Horta, S | 1 |
Campolongo, A | 1 |
Pascual-Sedano, B | 1 |
Marín-Lahoz, J | 1 |
Bejr-Kasem, H | 1 |
Labandeira-Garcia, JL | 1 |
Lanciego, JL | 1 |
Puig-Davi, A | 1 |
Horta-Barba, A | 1 |
Pagonabarraga, J | 1 |
Rodríguez-Antigüedad, J | 1 |
McDaniel, D | 1 |
Obideen, M | 1 |
Dee, E | 1 |
Shokouhi, M | 1 |
Quyyumi, AA | 1 |
Levey, A | 1 |
Goldstein, F | 1 |
Ahmed, HA | 2 |
Ishrat, T | 2 |
Pillai, B | 2 |
Bunting, KM | 1 |
Patel, A | 1 |
Vazdarjanova, A | 1 |
Waller, JL | 2 |
Arbab, AS | 1 |
Ergul, A | 2 |
Fagan, SC | 2 |
Tsuruya, K | 1 |
Yoshida, H | 1 |
Fouda, AY | 1 |
Sayed, MA | 1 |
Eldahshan, W | 1 |
Bosch, J | 1 |
O'Donnell, M | 1 |
Swaminathan, B | 1 |
Lonn, EM | 1 |
Sharma, M | 1 |
Dagenais, G | 1 |
Diaz, R | 1 |
Khunti, K | 1 |
Lewis, BS | 1 |
Avezum, A | 1 |
Held, C | 1 |
Keltai, M | 1 |
Reid, C | 1 |
Toff, WD | 1 |
Dans, A | 1 |
Leiter, LA | 1 |
Sliwa, K | 1 |
Lee, SF | 1 |
Pogue, JM | 1 |
Hart, R | 1 |
Yusuf, S | 1 |
Hart, M | 1 |
Chen, YL | 1 |
Mack, W | 1 |
Novak, V | 1 |
C Chui, H | 1 |
Lipsitz, L | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
CAndesartan vs LIsinopril Effects on the BRain and Endothelial Function in eXecutive MCI (CALIBREX)[NCT01984164] | Phase 2 | 176 participants (Actual) | Interventional | 2014-08-20 | Completed | ||
Heart Outcomes Prevention Evaluation-3[NCT00468923] | Phase 4 | 12,705 participants (Actual) | Interventional | 2007-05-31 | Completed | ||
The Antihypertensives and Vascular, Endothelial and Cognitive Function Trial (AVEC Trial)[NCT00605072] | Phase 2 | 53 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
"EXecutive Abilities: Measures and Instruments for Neurobehavioral Evaluation and Research or EXAMINER tool box. This test batteryThe battery includes 11 tasks that generate 15 primary variables. Within this set, the EXAMINER includes: working memory, inhibition, set shifting, and fluency. The parts of EXAMINER that were used for this study include: Flanker task (inhibition) which involves responding to a central stimulus while ignoring flanking stimuli that are either compatible or incompatible with the central stimulus; Set-shifting, a measure of mental flexibility; Spatial 1-Back test assesses spatial working memory; Dot Counting test assesses verbal working memory; Verbal Fluency tested using a List Generation test which require the participant to generate words beginning with a specific letter, and category fluency in which the participant generates words from a specified category (e.g., animals, fruits). Higher are reflective of better executive function (-1 to +1)" (NCT01984164)
Timeframe: 12 months
Intervention | units on a scale (Least Squares Mean) |
---|---|
Candesartan | 0.07 |
Lisinopril | 0.25 |
The Digit Span test is a subtest of both the Wechsler Adult Intelligence Scale (WAIS) and the Wechsler Memory Scales (WMS). For the digit span backwards, subjects are read a sequence of numbers and asked to repeat the same sequence back to the examiner in reverse order (backward span). Backward span is an executive task particularly dependent on working memory. The Digit Span backward is scored for backwards performance. Scale: 0 (minimum) to 16 (maximum). A higher score represents a better outcome. (NCT01984164)
Timeframe: 12 months
Intervention | Number of correct responses (Least Squares Mean) |
---|---|
Candesartan | 5.14 |
Lisinopril | 5.16 |
This will be measured using Digit Span Forward. The Digit Span test is a subtest of both the Wechsler Adult Intelligence Scale (WAIS) and the Wechsler Memory Scales (WMS). For the digit span forward, subjects are read a sequence of numbers and asked to repeat the same sequence back to the examiner in the correct order (forward span). Forward span captures attention efficiency and capacity. The Digit Span forward is scored for forwards performance. Scale: 0 (minimum) to 16 (maximum). A higher score represents a better outcome. (NCT01984164)
Timeframe: 12 months
Intervention | Number of correct responses (Least Squares Mean) |
---|---|
Candesartan | 9.67 |
Lisinopril | 8.93 |
ASL-MRI: Arterial Spin Labeling (ASL) MRI is non-invasive measure of perfusion that does not require contrast, and allows multiple brain regions mapping of perfusion and reserve. ASL-MRI provides measures of cerebral blood flow (CBF). Higher values indicates higher CBF. (NCT01984164)
Timeframe: 12 months
Intervention | ml/100g/min (Least Squares Mean) |
---|---|
Candesartan | 45.48 |
Lisinopril | 47.65 |
Executive function will be assessed using Trail Making Test (part B-A). Part A was collected to correct for motor speed and visual-perceptual demands on TMT by subtracting completion time for TMT Part A from completion time for Part B (TMT B - A). TMT Part B-A provides a relatively purer measure of executive functioning. It has a timed scale from 0 sec (min) to 300 secs (max). Along this scale, a lower score is better. (NCT01984164)
Timeframe: 12 months
Intervention | seconds (Least Squares Mean) |
---|---|
Candesartan | 87.23 |
Lisinopril | 111.37 |
This will be measured using the Boston Naming Test. BNT is a neuropsychological test used to assess visual confrontation naming and language performance in participants with cognitive decline. Its short 15-item version consists of drawings of objects ranging from common objects to less familiar objects. Scale: 0 (min score) to 15 (max score). For this test, a higher score/response represents a better outcome. (NCT01984164)
Timeframe: 12 months
Intervention | number of correct responses (Least Squares Mean) |
---|---|
Candesartan | 13.42 |
Lisinopril | 13.84 |
To assess episodic memory, the Hopkins Verbal Learning Test-Revised (HVLT-R) will be used. The retention (%) score is calculated by dividing the delayed recall trial by the higher of 3 learning trials. Each trial scores 0 (min) to 12 (max). The HVLT-R retention score is a percentage, and a higher percentage represents a better outcome. (NCT01984164)
Timeframe: 12 months
Intervention | percentage of retention (Least Squares Mean) |
---|---|
Candesartan | 82.71 |
Lisinopril | 79.47 |
White Matter Lesion volume: high-resolution anatomical images are acquired for the measurement of microvascular disease. WMH volumes will be obtained from Fluid attenuated inversion recovery (FLAIR) imaging sequence and reported as total volume (in mm3). Higher values means greater WMH (NCT01984164)
Timeframe: 12 months
Intervention | mm^3 (Least Squares Mean) |
---|---|
Candesartan | 2.68 |
Lisinopril | 5.73 |
This reports the change in the least square mean from baseline to 12 months, adjusted for age (NCT00605072)
Timeframe: Baseline-12 months
Intervention | cm/sec (Least Squares Mean) |
---|---|
ACEI (Lisinopril) | -0.3 |
ARB (Candesartan) | -2.85 |
HCTZ | 0.35 |
Blood pressure was measured as follows: the participant was in the sitting position, rested for 5 minutes, no caffeine or smoking 2 hours prior to measurement, using appropriate cuff size (covering 60% of upper arm length and 80% of arm circumference), correct cuff placement (1-2 inches above brachial pulse on bare arm), and the bell of the stethoscope. The systolic blood pressure was defined as the pressure corresponding to the first korotkoff sounds (K1) and the diastolic as the pressure corresponding to the last korotkoff sound (K5). Blood pressure was measured in both arms and recorded (NCT00605072)
Timeframe: Baseline-12 months
Intervention | mm Hg (Least Squares Mean) |
---|---|
ACEI (Lisinopril) | 28 |
ARB (Candesartan) | 27 |
HCTZ | 21 |
This test consists of series of digits of increasing length, some of which are recited as presented, and some of which are to be recited in reversed order. The forward digit span score ranges from 0 (ie cannot repeat two digits) to 8 ( participant can repeat up to 8 digits) (NCT00605072)
Timeframe: Baseline-12 months
Intervention | number of digits repeated (Least Squares Mean) |
---|---|
ACEI (Lisinopril) | -0.3 |
ARB (Candesartan) | 0.02 |
HCTZ | -0.04 |
This is a 12-item list learning test in which individuals are presented three learning and recall trials followed by a delayed recall and 24 item recognition test. The HVLT-R has been identified as an ideal memory measure for elderly patients, and appropriate reliability and validity have been shown in older individuals. The test score is the number of correct answers in the delayed recall ( score range 0-12) (NCT00605072)
Timeframe: Baseline-12 months
Intervention | number words remembered (Least Squares Mean) |
---|---|
ACEI (Lisinopril) | -1 |
ARB (Candesartan) | -2 |
HCTZ | -3 |
This test requires the connection of sequentially numbered circles (A), and the connection of circles marked by numbers and letters in alternating sequence (B). This test is considered a benchmark of executive function. The test score is the time required to complete the task in seconds. (NCT00605072)
Timeframe: Baseline-12 months
Intervention | seconds (Least Squares Mean) |
---|---|
ACEI (Lisinopril) | -14 |
ARB (Candesartan) | 17 |
HCTZ | 4 |
1 review available for candesartan and Cognitive Decline
Article | Year |
---|---|
Effects of candesartan on cerebral microvascular function in mild cognitive impairment: Results of two clinical trials.
Topics: Aged; Alzheimer Disease; Carbon Dioxide; Cognitive Dysfunction; Female; Humans; Lisinopril; Male; Ra | 2023 |
4 trials available for candesartan and Cognitive Decline
Article | Year |
---|---|
A randomized clinical trial of candesartan for cognitive impairment in Parkinson's disease.
Topics: Benzimidazoles; Cognition Disorders; Cognitive Dysfunction; Humans; Neuropsychological Tests; Parkin | 2023 |
Effects of Candesartan vs Lisinopril on Neurocognitive Function in Older Adults With Executive Mild Cognitive Impairment: A Randomized Clinical Trial.
Topics: Administration, Oral; Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Press | 2020 |
RAS modulation prevents progressive cognitive impairment after experimental stroke: a randomized, blinded preclinical trial.
Topics: Amyloid beta-Peptides; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood P | 2018 |
Antihypertensive therapy and cerebral hemodynamics in executive mild cognitive impairment: results of a pilot randomized clinical trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Pressure; C | 2013 |
3 other studies available for candesartan and Cognitive Decline
Article | Year |
---|---|
Role of angiotensin system modulation on progression of cognitive impairment and brain MRI changes in aged hypertensive animals - A randomized double- blind pre-clinical study.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl | 2018 |
Brain Atrophy and Cognitive Impairment in Chronic Kidney Disease.
Topics: Animals; Atrophy; Benzimidazoles; Biphenyl Compounds; Brain; Cognitive Dysfunction; Cyclic N-Oxides; | 2018 |
Effects of blood pressure and lipid lowering on cognition: Results from the HOPE-3 study.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cognition; Cognitive Dysfunction; | 2019 |